T-CURX develops personalized T cell therapies for cancer, leveraging a proprietary platform for improved patient outcomes.
T-CURX has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.
T-CURX's investors include Bayern Kapital, BioMedPartners, i&i Biotech Fund, HighLight Capital.
T-CURX is headquartered in Würzburg, Germany.
T-CURX develops personalized T cell therapies for cancer, leveraging a proprietary platform for improved patient outcomes.
T-CURX is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"T-CURX — Funding & Investors." VCBacked, December 17, 2025, https://www.vcbacked.co/company/t-curx. Accessed July 26, 2026.
VCBacked. (2025). T-CURX — Funding & Investors. Retrieved July 26, 2026, from https://www.vcbacked.co/company/t-curx
{{cite web |title=T-CURX — Funding & Investors |url=https://www.vcbacked.co/company/t-curx |website=VCBacked |access-date=July 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated